Table 3 Characteristics of patients with B-lymphoid neoplasm according to analyzed population (main analysis and overall population analyses).

From: Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis

 

Analyzed population

 

16-day anti-CD20 population

Overall population

 

Group

Group

 

CP+

CP–

CP+

CP–

 

N (%)

N (%)

N (%)

N (%)

All

32 (100)

115 (100)

81 (100)

120 (100)

Epidemic wave

1st—Mar–Jun 2020

2 (6)

81 (71)

19 (23)

94 (77)

2nd—Jul–Oct 2020

8 (25)

20 (17)

26 (32)

10 (8)

3rd—Nov–Dec 2020

18 (56)

13 (11)

32 (40)

11 (9)

4th—Jan–Apr 2021

4 (13)

1 (1)

4 (5)

5 (4)

Geographic area

Paris region

13 (41)

69 (60)

33 (41)

85 (71)

Eastern France

1 (3)

26 (23)

9 (11)

30 (25)

Other

18 (56)

20 (17)

39 (48)

5 (4)

Gender

Male

19 (59)

76 (66)

56 (69)

72 (60)

Female

13 (41)

39 (34)

25 (31)

48 (40)

Age (years)

<55

9 (28)

17 (15)

18 (22)

11 (9)

55–64

11 (35)

41 (36)

27 (33)

35 (29)

65–74

9 (28)

37 (32)

24 (30)

36 (30)

≥75

3 (9)

20 (17)

12 (15)

38 (32)

BMI (kg/m2)

<18.5

2 (6)

5 (4)

3 (4)

6 (5)

[18.5; 25]

14 (44)

56 (49)

34 (41)

61 (51)

[25; 30]

10 (31)

29 (25)

24 (30)

29 (24)

≥30

4 (13)

15 (13)

8 (10)

17 (14)

Missing

2 (6)

10 (9)

12 (15)

7 (6)

Arterial hypertension

No

27 (84)

80 (70)

69 (85)

70 (58)

Yes

5 (16)

35 (30)

12 (15)

50 (42)

Diabetes

No

30 (94)

98 (85)

76 (94)

93 (77)

Yes

2 (6)

17 (15)

5 (6)

27 (23)

AH or diabetes or BMI >25 kg/m2—PS*

No

14 (44)

52 (45)

41 (51)

45 (38)

Yes

18 (56)

63 (55)

40 (49)

75 (63)

WHO scale at hospitalization

Missing

0 (0)

2 (2)

0 (0)

6 (5)

WHO 4

8 (25)

41 (36)

29 (36)

33 (28)

WHO 5

22 (69)

58 (50)

44 (55)

69 (57)

WHO 6

2 (6)

7 (6)

6 (7)

6 (5)

WHO 7

0 (0)

7 (6)

2 (2)

6 (5)

Anti-CD20 mAbs

No

0 (0)

0 (0)

3 (4)

26 (22)

Yes

32 (100)

115 (100)

78 (96)

94 (78)

Corticotherapy—PS*

No

11 (34)

67 (58)

29 (36)

83 (69)

Yes

21 (66)

48 (42)

52 (64)

37 (31)

Tocilizumab

No

31 (97)

106 (92)

75 (93)

115 (96)

Yes

1 (3)

9 (8)

6 (7)

5 (4)

Azithromycin-hydroxychloroquine

No

32 (100)

107 (93)

79 (98)

109 (91)

Yes

0 (0)

8 (7)

2 (2)

11 (9)

Remdesivir

No

29 (91)

107 (93)

72 (89)

117 (98)

Yes

3 (9)

8 (7)

9 (11)

3 (3)

B-cell lymphoid neoplasm

Chronic lymphocytic leukemia

6 (19)

11 (10)

13 (16)

18 (15)

Diffuse large B-cell lymphoma

12 (37)

48 (41)

28 (35)

49 (42)

Follicular lymphoma

6 (19)

32 (28)

23 (28)

22 (18)

Marginal zone lymphoma

1 (3)

10 (9)

4 (5)

16 (13)

Mantle cell lymphoma

5 (16)

13 (11)

11 (14)

11 (9)

Waldenström macroglobulinemia

2 (6)

1 (1)

2 (2)

4 (3)

  1. The proportion of treated patients differed greatly among the strata of variables included in the propensity score such as age: 54% of treated in <65 years vs. 36% in ≥65 years in RCT-like population, 48% of treated in absence of comorbidity vs. 35% in presence of comorbidity in the overall population, 14% of treated in patients not receiving corticotherapy vs. 30% in patients receiving corticotherapy. Moreover, this table shows that the proportion of treated patients differed also for variables that could not be included in the propensity score but defined sensitivity analysis populations such as wave, pre-exposure to anti-CD20, and area of hospitalization.
  2. CP convalescent plasma, AH arterial hypertension, BMI body mass index, PS* included in the propensity score, N number of patients, WHO World Health Organization, mAbs monoclonal antibodies.
Back to article page